Skip to main content

Generic Vocabria Availability

Last updated on Jun 8, 2022.

Vocabria is a brand name of cabotegravir, approved by the FDA in the following formulation(s):

VOCABRIA (cabotegravir sodium - tablet;oral)

  • Manufacturer: VIIV HLTHCARE
    Approval date: January 21, 2021
    Strength(s): EQ 30MG BASE [RLD]

Has a generic version of Vocabria been approved?

No. There is currently no therapeutically equivalent version of Vocabria available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vocabria. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,927,129

    Patent expiration dates:

    • April 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
    Patent 8,410,103
    Issued: April 2, 2013
    Assignee(s): Shionogi & Co., Ltd. VIIV Healthcare Company

    The present invention is directed to a substituted 2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2 -a]pyrido[1,2-d]pyrazine-5,7-dione useful as an anti-HIV agent, which has the formula: as well as pharmaceutically acceptable salts thereof, compostions thereof, and methods of use thereof.

    Patent expiration dates:

    • April 28, 2026
      ✓ 
      Patent use: TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 28, 2026
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • January 31, 2025 - REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 207966 ATLAS-2M
    • March 29, 2025 - NEW PATIENT POPULATION
    • January 21, 2026 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.